Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy. Indeed, modulating immune inhibitory pathways has been considered an important breakthrough in cancer treatment. Although immune checkpoint blockade therapy used to treat malignant diseases has provided promising results, both solid and haematological malignancies develop mechanisms that enable themselves to evade the host immune system. To overcome some major limitations and ensure safety in patients, recent strategies have shown that combining epigenetic modulators, such as inhibitors of histone deacetylases (HDACi) or DNA methyltransferases (DNMTi), with immunotherapeutics can be useful. Preclinical data generated using mouse models strongly support the feasibility and effectiveness of the proposed approaches. Indeed, co-treatment with pan- or class I-selective HDACi or DNMTi improved beneficial outcomes in both in vitro and in vivo studies. Based on the evidence of a pivotal role for HDACi and DNMTi in modulating various components belonging to the immune system, recent clinical trials have shown that both HDACi and DNMTi strongly augmented response to anti-PD-1 immunotherapy in different tumour types. This review describes the current strategies to increase immunotherapy responses, the effects of HDACi and DNMTi on immune modulation, and the advantages of combinatorial therapy over single-drug treatment.

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy / Mazzone, Roberta; Zwergel, Clemens; Mai, Antonello; Valente, Sergio. - In: CLINICAL EPIGENETICS. - ISSN 1868-7083. - STAMPA. - 9:1(2017), pp. 1-15. [10.1186/s13148-017-0358-y]

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy

MAZZONE, ROBERTA;ZWERGEL, CLEMENS;MAI, Antonello;VALENTE, Sergio
2017

Abstract

Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy. Indeed, modulating immune inhibitory pathways has been considered an important breakthrough in cancer treatment. Although immune checkpoint blockade therapy used to treat malignant diseases has provided promising results, both solid and haematological malignancies develop mechanisms that enable themselves to evade the host immune system. To overcome some major limitations and ensure safety in patients, recent strategies have shown that combining epigenetic modulators, such as inhibitors of histone deacetylases (HDACi) or DNA methyltransferases (DNMTi), with immunotherapeutics can be useful. Preclinical data generated using mouse models strongly support the feasibility and effectiveness of the proposed approaches. Indeed, co-treatment with pan- or class I-selective HDACi or DNMTi improved beneficial outcomes in both in vitro and in vivo studies. Based on the evidence of a pivotal role for HDACi and DNMTi in modulating various components belonging to the immune system, recent clinical trials have shown that both HDACi and DNMTi strongly augmented response to anti-PD-1 immunotherapy in different tumour types. This review describes the current strategies to increase immunotherapy responses, the effects of HDACi and DNMTi on immune modulation, and the advantages of combinatorial therapy over single-drug treatment.
2017
cancer; DNA methylation; epigenetics; HDAC inhibitors; immune checkpoint inhibitors; immunotherapy
01 Pubblicazione su rivista::01a Articolo in rivista
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy / Mazzone, Roberta; Zwergel, Clemens; Mai, Antonello; Valente, Sergio. - In: CLINICAL EPIGENETICS. - ISSN 1868-7083. - STAMPA. - 9:1(2017), pp. 1-15. [10.1186/s13148-017-0358-y]
File allegati a questo prodotto
File Dimensione Formato  
Mazzone_Epi-drugs_2017.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 772.87 kB
Formato Adobe PDF
772.87 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/972511
Citazioni
  • ???jsp.display-item.citation.pmc??? 73
  • Scopus 118
  • ???jsp.display-item.citation.isi??? 111
social impact